About Neosil
Neosil is a company based in Palo Alto (United States) founded in 2003 was acquired by Peplin in June 2008. Neosil has raised $32 million across 2 funding rounds from investors including Hercules Capital, Burrill and Company and Peplin. Neosil operates in a competitive market with competitors including Revance Therapeutics, Castle Creek Pharma, Dermavant, Sol-Gel Technologies and Bausch Health, among others.
- Headquarter Palo Alto, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$32 M (USD)
in 2 rounds
-
Latest Funding Round
$10 M (USD), Debt – Venture
May 02, 2007
-
Investors
Hercules Capital
& 3 more
-
Employee Count
Not available
-
Acquired by
Peplin
(Jun 13, 2008)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Neosil
Neosil has successfully raised a total of $32M across 2 strategic funding rounds. The most recent funding activity was a Debt – Venture round of $10 million completed in May 2007. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Neosil
Neosil has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include Hercules Capital, Burrill and Company and Peplin.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture debt financing is provided to companies in multiple sectors.
|
Locked | Locked | Locked | |
|
Invests in biotech firms developing life-saving drugs and technologies.
|
Locked | Locked | Locked | |
|
Multi-category products are listed on an online B2B platform.
|
Locked | Locked | Locked |
Investor details for Neosil
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Neosil
Investment portfolio details for Neosil
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Neosil
Detailed financials for Neosil
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Neosil Comparisons
Peer comparison for Neosil
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Neosil
Neosil operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Revance Therapeutics, Castle Creek Pharma, Dermavant, Sol-Gel Technologies and Bausch Health, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Neurotoxin products for aesthetic and therapeutic skin treatments are developed.
|
|
| Locked | Locked | Locked |
Drugs for skin diseases, ENT disorders, and rare diseases such as urea cycle disorders
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for inflammatory skin diseases are developed.
|
|
| Locked | Locked | Locked |
Developing topical drug products for the treatment of rosacea, acne and interdigital tinea pedis.
|
|
| Locked | Locked | Locked |
Therapeutics for multiple diseases including dermatology and neurology are developed.
|
|
| Locked | Locked | Locked |
Therapeutics in aesthetics are developed, including botulinum toxin products.
|
Detailed competitors of Neosil
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Neosil
Complete news archive for Neosil
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Neosil
Neosil was founded in 2003 and raised its 1st funding round 1 year after it was founded.
Neosil is headquartered in Palo Alto, United States. It is registered at Palo Alto, California, United States.
Gene Bauer is the current CEO of Neosil.
Neosil is a funded company, having raised a total of $32M across 2 funding rounds to date.
Neosil was established in 2003 in Palo Alto, United States, as a specialty pharmaceutical company centered on dermatology. Operations involved the development of products like NEOSH101 for hair growth and broad-spectrum anti-microbial agents targeting acne. The firm was led by CEO Gene Bauer. Acquisition by Peplin occurred in October 2008, concluding independent activities.
Neosil's top competitors include Revance Therapeutics, Dermavant and Bausch Health.
Neosil has 4 investors. Key investors include Hercules Capital, Burrill and Company, Peplin, and Turmeric Acquisition Corp.